Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non-Current Deffered Revenue (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 5.97% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, down 5.97%, while the annual FY2025 figure was $3.0 million, 5.97% down from the prior year.
  • Non-Current Deffered Revenue was $3.0 million for Q4 2025 at Day One Biopharmaceuticals, up from $3.0 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $3.4 million in Q2 2025, with the low at $3.0 million in Q3 2025.